Ovid TherapeuticsOVID
Recorded

Ovid Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matthew TanAnalyst

Welcome. My name is Matthew Tan. I am here for Paul Matteis, and I am very pleased to be joined by Meg Alexander, President and CEO from Ovid Therapeutics. Thank you so much for joining us today. I know you guys have a lot of exciting catalysts coming up. Maybe do you want to give us an overview, starting with KCC2, and then we can move on from there?

Meg AlexanderPresident and CEO

Sure. I am happy to. Matthew and Steve and team, thank you for hosting us. I am the CEO of Ovid Therapeutics, and it is a really exciting time for Ovid. I tease our team that we are in the playoffs, and the reason why is we have a number of programs that have what I think will be very exciting card turnovers or data milestones in the span of the next six and 12 months. I will start maybe just quickly, I will acclimate everyone to the company and then the pipeline, and we can absolutely dig into KCC2, and that will be fun. Ovid is a neurotherapeutics company. We are a company that exists to try to make better and gentler medicines for brain conditions, both neurology and neuropsychiatry.

Meg AlexanderPresident and CEO

The way we did this and the way that we developed the company and the pipeline that you see in front of you is we very deliberately went out and we tried to look at targets that we thought had relevance across a number of conditions that drive essentially too much excitation of your neurons. We tried to do and drug those targets with truly differentiated mechanisms of action. Unfortunately, in the world of neurology and really even psychiatry, there have not been new mechanisms that have come to the fore, and as a result, we are not really seeing a step change for patients. That was very intentional on our part in how we curated the pipeline, and we only do small molecule medicines. We want medicines that are easy for patients to use, and this is the area and modality that we are strong at.

Meg AlexanderPresident and CEO

That strategy has helped us build the pipeline that you see in front of you. I will start at the bottom in a moment, but basically, we have a pipeline that has two very different mechanisms of action in it. One is an anticonvulsant mechanism, and that program is at the top in these kind of teal buckets, and that is called OV329, and it is a mechanism that is a validated anticonvulsant mechanism. It is validated in seizures and epilepsies, but the only other company that tried to develop for this mechanism had a kind of first-generation drug that had a compound-specific toxicity. We had to work on that.

Meg AlexanderPresident and CEO

We've done so, and now we've got multiple epilepsy programs for the program OV329, both in adult epilepsies, but also in a number of very bad pediatric epilepsies, and specifically developmental and epileptic encephalopathies, where our drug, this inhibition of an enzyme that degrades the main inhibitory neurotransmitter, GABA, is inhibited basically. We'll talk about that in a few minutes, but what I'm really excited to talk about is exactly what Matthew Tan suggested, which is our KCC2 direct activator. KCC2 may sound like some kind of Soviet rocket ship, but it's actually been a long wanted to be target, drug to target rather, for the brain. The reason why is it's a very special target. It's only in the brain. Essentially, when it doesn't work, the braking system in our brains, GABA, the main inhibitory neurotransmitter, can't do its job, can't be functional.

Meg AlexanderPresident and CEO

It's been very, very difficult to drug. Lots of people have tried to do this for more than 20 years because it potentially has very broad therapeutic utility, which we'll talk about in a moment. But now we've finally done it. We've solved chemistry, formulation challenges, other characterization challenges, and we have a really exciting molecule, OV4071, in the clinic in a phase I study, and we're soon to trigger actually a pretty exciting translational study there, which will tell us even more about how directly activating KCC2 may have therapeutic potential. I'll take a pause there, and we can dive into KCC2 next if that's where you want to go. Okay, great. You'll have to forgive me because it's the earlier part of the pipeline. We're going to have to flip through a lot of slides, and then we're going to have to back it up again.

Meg AlexanderPresident and CEO

It's kind of fun to start with this one because this is the program that, while it's the earliest, I think is one of the ones that investors are most excited about now. I'm excited about both. We love all of our children in our pipeline. KCC2, I started on this a few moments ago, but why is this target a big deal? The reason why is it is potentially a master switch on neural hyperexcitability, and there's some really important things about that. The one is what I said before, which is the main braking system in our brain, the main inhibitory neurotransmitter, GABA, can't be hyperpolarizing. It can't be functional if this particular target doesn't balance the right amount of ions in and out of a neuron.

Meg AlexanderPresident and CEO

That's essentially what this target's job is, KCC2, is to pump out enough chloride that now enables GABA to be inhibitory. What's exciting about it is it's only expressed in the CNS. Unlike a lot of other ion transporters that drug developers like me have tried to drug, we don't see the same tolerability and safety profile because it's not expressed in other tissues and organs in the body. Unlike other things that we do in the CNS, you can't over-modulate this target. Its job is to balance ions, as I mentioned, potassium and chloride. It's almost impossible to get it to spit out too much chloride. It's more precise in what it does, where other things in the brain, we're always trying to get this balance right.

Meg AlexanderPresident and CEO

Finally, there was always literature that suggested that drugging this target may have very broad applications, everywhere from seizures and pain and epilepsies to autism, and interestingly, a lot of basically psychiatric symptoms as well. But no one officially ever had a direct activator to be able to prove it, and now we do, and we are, and we are actively doing that. I have talked about the way it works. I do not think we need to talk so much about the mechanism. I think what is more exciting to do is to talk about this molecule that is in the clinic and performing.

Meg AlexanderPresident and CEO

What we know today about OV4071, which is an oral direct activator of KCC2, which means it is going to be, we believe, very amenable for chronic use across a number of conditions, is that we, for starters, when you talk about first in human biology, safety and tolerability profile matters, and we have not only superb safety margins in animals, we are in a phase I study right now, and that is going well. We have gone through several SAD cohorts. We have moved into the MAD portion, and feeling very good about the prospects. What is also exciting about this particular molecule, OV4071, is that it is very potent, it is highly consistent, frankly, in a way that I have never seen a molecule perform in my career to date, and I am not young. Been in healthcare for 25 years. It seems to have extremely broad neuroactivity.

Meg AlexanderPresident and CEO

What I mean by that is no one ever had one of these to be able to test what could drugging KCC2 do, and now we are actually seeing, in animals albeit, we are trying to prove this very shortly in humans, we are seeing the types of activity that the literature always hinted at, but no one could actually prove before. We are seeing profound activity in areas of psychosis domains. We have run more than 100 pharmacology and pharmacodynamic studies across this program and our tool program, and we are seeing rapid activity to essentially rescue various symptoms of positive symptoms of psychosis. We are seeing it work very well in negative symptom domains and in enhancement in cognition, which is the holy grail in areas of psychosis that, unfortunately, as a field, we have not been able to achieve yet.

Meg AlexanderPresident and CEO

It is very exciting, and it has got the right drug-like properties to be able to be developed in the clinic. I started to talk about some of the domains where we have seen activity. This is an eye chart that if you can read this in the back row, I would be very impressed. What it essentially is showing is some of what the literature has suggested, right? Now that we are able to prove in animals, in genetic, behavioral, stimulant, different animal models of pharmacology, but we now have more than 40 studies in psychosis that are very encouraging, highly consistent, and they have been repeated and validated across many CROs. We believe in the evidence. We are also seeing exciting data in areas like Rett, interesting signals in pain and seizures.

Meg AlexanderPresident and CEO

We have more work to do there, but the opportunity of drugging KCC2 may actually be this profound. As I said before, we are in a phase I study right now, so that is going quite well, and once we get to a certain stage in that study, we are planning to trigger another translational study, which is called a ketamine challenge. That sometimes raises eyebrows, but what essentially this study allows us to do is to make the target, KCC2, less functional in the brain, and to essentially make the brain a little bit more like someone who had a form of psychosis in a resting state. Then what we are able to do is essentially look, is OV4071 getting into the brain? Is it neuroactive? Is it acting on mechanism? We can look at this through things like electrophysiology, things like EEG, ERP.

Meg AlexanderPresident and CEO

Then finally, we have a number of biomarkers in this ketamine challenge that allow us to look into the brain and seeing are we correcting or bringing back to a normal physiological state the neurotransmission in the brain such that we have essentially made somebody like you, Matthew, with the ketamine, have a brain that is having aberrant activity, more like someone with schizophrenia at rest. So, giving 4071, can we return the neurotransmission to closer to a typical physiological state? We run a number of biomarkers in the study, a big battery of them, that help us look at the signatures that happen when someone has something like a resting state of schizophrenia on certain biomarker panels, and can we correct those with OV4071? Why we do all that is we can actually get early insights into predictive clinical effect.

Meg AlexanderPresident and CEO

We can say, "Okay, is what we are doing in a human matching all these studies that we have run in animals?" It helps us make smart decisions about the indications that we are pursuing as well as the endpoints that we are pursuing. I am very excited by that, and we are planning to go into acute schizophrenia around the middle of next year, as the initial proof of concept study. We think this is a very big drug in terms of its antipsychotic opportunity. We are starting with acute schizophrenia. If we see the right signals there, we think we could go much broader than that into various neurodegenerative forms of psychosis. But the biological rationale for drugging KCC2 in schizophrenia has been there. We know in people, in post-mortem data for people who have schizophrenia, that they have reduced KCC2 expression in the prefrontal cortex.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day